Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial.

Saved in:
Bibliographic Details
Title: Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial.
Authors: Brudno JN; Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Natrakul DA; Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Karrs J; Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Patel N; Hematology Section, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD., Maass-Moreno R; Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, MD., Ahlman MA; Department of Radiology and Imaging, Medical College of Georgia, Augusta, GA., Mikkilineni L; Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Mann J; Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Stroncek DF; Center for Cellular Engineering, Clinical Center, National Institutes of Health, Bethesda, MD., Highfill SL; Center for Cellular Engineering, Clinical Center, National Institutes of Health, Bethesda, MD., Fromm GC; Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Patel R; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Pittaluga S; Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Kochenderfer JN; Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Source: Blood advances [Blood Adv] 2024 Feb 13; Vol. 8 (3), pp. 802-814.
Publication Type: Clinical Trial, Phase I; Journal Article
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2473-9537
DOI:10.1182/bloodadvances.2023011470